Provided by Tiger Fintech (Singapore) Pte. Ltd.

Hookipa Pharma Inc

1.34
-0.0500-3.60%
Pre-market: 1.340.00000.00%08:00 EST
Volume:22.44K
Turnover:31.37K
Market Cap:13.27M
PE:-0.38
High:1.46
Open:1.38
Low:1.34
Close:1.39
Loading ...

Company Profile

Company Name:
Hookipa Pharma Inc
Exchange:
NASDAQ
Establishment Date:
2011
Employees:
165
Office Location:
350 Fifth Avenue,72nd Floor,Suite 7240,New York,New York,United States
Zip Code:
10118
Fax:
- -
Introduction:
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.

Directors

Name
Position
Jan van de Winkel
Chairman of the Board, Director
Jorn Aldag
Chief Executive Officer, Director
Reinhard Kandera
Chief Financial Officer, Director
Christoph Lengauer
Director
Graziano Seghezzi
Director
Julie O'Neill
Director
Michael A. Kelly
Director
Paul Henri Lambert
Director
Sander van Deventer
Director

Shareholders

Name
Position
Jorn Aldag
Chief Executive Officer, Director
Anders Lilja
Senior Vice President Technical Development
Klaus Orlinger
Senior Vice President Research
Reinhard Kandera
Chief Financial Officer, Director
Daniel Pinschewer
Chief Scientific Officer
Igor Matushansky
Chief Medical Officer and Global Head of Research and Development